Kelly Patricia Burke, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immune System Diseases | 1 | 2023 | 258 | 0.710 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2023 | 4554 | 0.580 |
Why?
|
Autoimmunity | 2 | 2023 | 1370 | 0.530 |
Why?
|
Hepacivirus | 3 | 2012 | 1333 | 0.520 |
Why?
|
Immunotherapy | 6 | 2024 | 4637 | 0.470 |
Why?
|
Immune Tolerance | 1 | 2021 | 2299 | 0.390 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2250 | 0.390 |
Why?
|
Melanoma | 3 | 2023 | 5695 | 0.340 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3826 | 0.320 |
Why?
|
T-Lymphocytes | 4 | 2024 | 10183 | 0.280 |
Why?
|
Immune Evasion | 1 | 2010 | 362 | 0.280 |
Why?
|
Neoplasms | 5 | 2023 | 22066 | 0.280 |
Why?
|
Hepatitis C | 2 | 2012 | 1578 | 0.240 |
Why?
|
Antigens, Neoplasm | 2 | 2023 | 1999 | 0.210 |
Why?
|
Friends | 1 | 2024 | 150 | 0.210 |
Why?
|
Hepatitis C, Chronic | 1 | 2010 | 1031 | 0.200 |
Why?
|
Immunoglobulins | 1 | 2024 | 863 | 0.180 |
Why?
|
Antibodies, Neutralizing | 1 | 2010 | 1933 | 0.180 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2020 | 83 | 0.170 |
Why?
|
Peptide Fragments | 1 | 2012 | 5120 | 0.170 |
Why?
|
Orthomyxoviridae Infections | 1 | 2020 | 250 | 0.150 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 3217 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2023 | 2536 | 0.140 |
Why?
|
Receptors, Immunologic | 1 | 2023 | 1434 | 0.130 |
Why?
|
Ligands | 1 | 2023 | 3277 | 0.130 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 429 | 0.120 |
Why?
|
Microsatellite Instability | 1 | 2018 | 715 | 0.120 |
Why?
|
Leukemia | 1 | 2022 | 1522 | 0.110 |
Why?
|
Immunologic Memory | 1 | 2020 | 1354 | 0.110 |
Why?
|
Antigen Presentation | 1 | 2019 | 1254 | 0.110 |
Why?
|
Antigens, CD | 1 | 2024 | 4002 | 0.110 |
Why?
|
DNA Repair | 2 | 2019 | 2039 | 0.100 |
Why?
|
Viral Hepatitis Vaccines | 1 | 2012 | 75 | 0.100 |
Why?
|
Genes, Synthetic | 1 | 2012 | 88 | 0.100 |
Why?
|
Consensus Sequence | 1 | 2012 | 367 | 0.100 |
Why?
|
Genome | 1 | 2019 | 1739 | 0.090 |
Why?
|
Cross Reactions | 1 | 2012 | 818 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2368 | 0.090 |
Why?
|
Colonic Neoplasms | 1 | 2021 | 2526 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5230 | 0.080 |
Why?
|
Genome, Viral | 1 | 2012 | 658 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8498 | 0.070 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7593 | 0.070 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 1720 | 0.070 |
Why?
|
Humans | 17 | 2024 | 760261 | 0.070 |
Why?
|
HLA Antigens | 1 | 2012 | 1369 | 0.070 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2010 | 825 | 0.070 |
Why?
|
Mutation | 5 | 2023 | 29950 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3613 | 0.070 |
Why?
|
Genomics | 2 | 2018 | 5790 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2021 | 4312 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2021 | 6310 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6855 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6540 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2018 | 9388 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5797 | 0.050 |
Why?
|
Cell Line | 2 | 2012 | 15626 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5333 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 383 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 642 | 0.040 |
Why?
|
Signal Transduction | 2 | 2020 | 23363 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 2020 | 471 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13629 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 788 | 0.040 |
Why?
|
Cells, Cultured | 1 | 2012 | 18968 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 730 | 0.030 |
Why?
|
Species Specificity | 1 | 2020 | 2413 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11341 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1090 | 0.030 |
Why?
|
Cell Death | 1 | 2020 | 1670 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1075 | 0.030 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2019 | 633 | 0.030 |
Why?
|
Animals | 5 | 2022 | 167940 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2052 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2022 | 2204 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 22025 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1483 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2003 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2008 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2024 | 3076 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1843 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1740 | 0.020 |
Why?
|
Cohort Studies | 1 | 2012 | 41317 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6775 | 0.020 |
Why?
|
Virus Internalization | 1 | 2012 | 494 | 0.020 |
Why?
|
Prospective Studies | 1 | 2012 | 54263 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5640 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5745 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 3618 | 0.020 |
Why?
|
Viral Proteins | 1 | 2012 | 1802 | 0.010 |
Why?
|
Phylogeny | 1 | 2012 | 2775 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81216 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10434 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16905 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2020 | 11480 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11708 | 0.010 |
Why?
|
Computational Biology | 1 | 2012 | 3504 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 17628 | 0.010 |
Why?
|
Genotype | 1 | 2012 | 12959 | 0.010 |
Why?
|
Male | 3 | 2021 | 359413 | 0.010 |
Why?
|
Aged | 2 | 2018 | 168995 | 0.010 |
Why?
|
Middle Aged | 2 | 2018 | 220175 | 0.010 |
Why?
|
Adult | 2 | 2018 | 219847 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2018 | 58947 | 0.010 |
Why?
|
Female | 2 | 2021 | 391011 | 0.010 |
Why?
|